Deutsche Bank AG Has $1.59 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Deutsche Bank AG reduced its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 67.1% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 213,382 shares of the company's stock after selling 434,466 shares during the quarter. Deutsche Bank AG owned 0.31% of EyePoint Pharmaceuticals worth $1,590,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Summit Investment Advisors Inc. grew its position in shares of EyePoint Pharmaceuticals by 39.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,838 shares of the company's stock valued at $51,000 after purchasing an additional 1,940 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter worth $59,000. Virtus ETF Advisers LLC bought a new stake in shares of EyePoint Pharmaceuticals during the fourth quarter worth $67,000. AlphaQuest LLC raised its holdings in shares of EyePoint Pharmaceuticals by 13,246.6% during the fourth quarter. AlphaQuest LLC now owns 9,743 shares of the company's stock worth $73,000 after acquiring an additional 9,670 shares during the period. Finally, Raymond James Financial Inc. bought a new stake in EyePoint Pharmaceuticals in the 4th quarter valued at $76,000. Institutional investors and hedge funds own 99.41% of the company's stock.

EyePoint Pharmaceuticals Stock Performance

NASDAQ EYPT traded up $0.17 during trading hours on Thursday, hitting $7.21. 757,824 shares of the company traded hands, compared to its average volume of 822,810. The business's 50-day moving average is $5.84 and its 200-day moving average is $7.01. The stock has a market capitalization of $496.13 million, a price-to-earnings ratio of -3.61 and a beta of 1.58. EyePoint Pharmaceuticals, Inc. has a twelve month low of $3.91 and a twelve month high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. The company had revenue of $24.50 million for the quarter, compared to analysts' expectations of $8.84 million. Analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday. Wall Street Zen raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Finally, Mizuho reduced their price target on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.38.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.